Samay

Samay is an innovative startup in the healthcare industry, dedicated to revolutionizing respiratory care and management. Founded in 2018 and headquartered in the United States, the company has garnered attention with its AI-driven acoustic resonance platform aimed at empowering patients, caregivers, and clinicians with crucial health information at home.

The startup has made significant strides, receiving backing from prestigious entities such as the NSF and NIH, showcasing the credibility of its technology. Samay's patented "acoustic resonance" technology is a game-changer in respiratory health, enabling the early detection of air trapping, a sensitive marker of lung dysfunction. This technology has the potential to accurately diagnose and predict deterioration, with the capability to anticipate exacerbations 4+ days in advance using low-cost, over-the-counter sensors that are 10x cheaper.

Notably, the company received a Non-Equity Assistance investment on 29th May 2024 from MedTech Innovator, further solidifying its position in the industry and signaling confidence from prominent investors.

Samay's dedication to leveraging advanced technology for respiratory health, coupled with its strategic partnerships and financial backing, positions the startup as a pivotal player in shaping the future of healthcare and respiratory disease prevention.